Key result
A monoclonal antibody (Mab-PAR-1) against the PeV-A1-VP0 protein successfully recognized 19 PeV-A1 isolates and 5 other parechovirus types without cross-reacting with entero- or rhinoviruses.
Why the study?
High-quality antibodies with broad binding specificities are essential to improve accurate parechovirus diagnosis and have potential in rapid antigen detection assay development.
The developed monoclonal antibody Mab-PAR-1 demonstrates broad reactivity against multiple parechovirus types without cross-reactivity to entero- and rhinoviruses, indicating potential for rapid antigen detection assays.
May enable parechovirus antigen assays; leaves open human validation and clinical utility.
Parechoviruses (PeVs) are common viruses that cause mild gastrointestinal or respiratory symptoms to severe central nervous system infections. In infants, parechovirus infection is one of the leading causes of life-threatening viral disease. High-quality antibodies with broad binding specificities are essential to improve accurate parechovirus diagnosis in diagnostic laboratories. Such antibodies have potential in the development of rapid antigen detection assay against PeVs. In the present study, VP4 and VP2 genes from human parechovirus A1 (PeV-A1) were cloned and VP0 fusion protein produced to develop monoclonal antibodies against PeVs. Two pan-parechovirus antibodies, one IgG and one IgM isotype, were isolated. The properties of IgG1/κ monoclonal (designated as Mab-PAR-1) was studied further. Mab-PAR-1 was shown to be functional in western blot against denatured recombinant protein and viral particles. In immunofluorescence assay, the antibody tested positive for nineteen PeV-A1 isolates while showing no cross-reactivity to fourteen entero- and rhinovirus types. In addition, Mab-PAR-1 showed positive reactivity against five other cultivable parechovirus types 2-6. A unique Mab-PAR-1 epitope located in the junction of the three capsid proteins VP0, VP1, and VP3 was identified using a peptide library screen. This study demonstrates that PeV-A1-VP0 protein is functional antigen for developing monoclonal antibody for diagnosis of broad range of parechovirus infections.
No takes yet. Share an insight, caveat, or question.
Tripathi et al. (2021) studied Parechovirus infection. Mab-PAR-1 (monoclonal antibody against VP0) was evaluated on Antibody reactivity and cross-reactivity. A monoclonal antibody (Mab-PAR-1) against the PeV-A1-VP0 protein successfully recognized 19 PeV-A1 isolates and 5 other parechovirus types without cross-reacting with entero- or rhinoviruses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: